A review of olanzapine-associated toxicity and fatality in overdose

Journal of Psychiatry and Neuroscience

Volumn 28, Issue 4, 2003, Pages 253-261

  Chue, Pierre ^a,c   Singer, Peter ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Office of the Chief Medical Examiner   (Canada)

^c NONE   (Canada)

Author keywords

Adverse drug reaction reporting systems; Antipsychotic agents; Drug toxicity; Olanzapine; Overdose; Suicide

Indexed keywords

ALCOHOL; ALPRAZOLAM; AMFEBUTAMONE; CITALOPRAM; CODEINE; DIPHENHYDRAMINE; FLUOXETINE; LORAZEPAM; LOXAPINE; LY 170222; METOCLOPRAMIDE; OLANZAPINE; OXAZEPAM; OXYCODONE; PAROXETINE; PHENYTOIN; PROCYCLIDINE; RISPERIDONE; VALPROIC ACID; VENLAFAXINE;

AUTOPSY; CANADA; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG OVERDOSE; FATALITY; HUMAN; MEDICAL LITERATURE; MORTALITY; REVIEW;

EID: 0141790782     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Beasley CM. Safety of olanzapine. J Clin Psychiatry 1997;15:19-21.
2. Gomez JC, Sacristan JA, Hernandez J, Breier A, Ruiz Carrasco P, Anton Saiz C, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). J Clin Psychiatry 2000;61:335-43.
3. Dougherty TJ, Greene TF, Farrell SE, Roberts JR. Adult and pediatric olanzapine overdose [abstract A165]. J Toxicol Clin Toxicol 1997;35:550.
4. Dobrusin M, Lokshin P, Belmaker RH. Acute olanzapine overdose. Hum Psychopharmacol 1999;14:355-6.
5. Schwartz JL. A new atypical antipsychotic. In: Schwartz JL, editor. Psychiatric times' advances in psychopharmacology. Irvine (CA): CME Inc.; 1997. p. 5-47.
6. Cohen LG, Fatalo A, Thompson BT, Bergeron GDC, Flood JG, Poupolo PR. Olanzapine overdose with serum concentrations. Ann Emerg Med 1999;34:275-8.
7. Bosch RF, Baumbach A, Bitzer M, Erley CM. Intoxication with olanzapine. Am J Psychiatry 2000;157:304-5.
8. Powell G, Nelson L, Hoffman R. Overdose with olanzapine (Zyprexa), a new antipsychotic agent [abstract A166]. J Toxicol Clin Toxicol 1997;35:550.
9. O'Malley GF, Sifert S, Heard K, Daly F, Dart RC. Olanzapine overdose mimicking opioid intoxication. Ann Emerg Med 1999;34:279-81.
10. O'Malley GF, Sifert S, Heard K, Yip L. Pupillary effects of olanzapine overdose mimic opiate and alpha-2 agonists [abstract[. J Toxicol Clin Toxicol 1998;36:523.
11. Fogel J, Diaz JE. Olanzapine overdose. Ann Emerg Med 1998;32:275-6.
12. Chambers RA, Caracansi AM, Weiss G. Olanzapine overdose cause of acute extrapyramidal symptoms. Am J Psychiatry 1998;155:1630-1.
13. Yip L, Graham K. Clinical effects of olanzapine in a 2fi-year-old male [abstract A164]. J Toxicol Clin Toxicol 1997;35:549-50.
14. Yip L, Dart RC, Graham K. Olanzapine toxicity in a toddler [letter]. Pediatrics 1998;102:1494-5.
15. Catalano G, Cooper DS, Catalano MC, Butera AS. Olanzapine overdose in an 18-month-old child. J Child Adolesc Psychopharmacol 1999;9:267-71.
16. Bonin MM, Burkhart KK. Olanzapine overdose in a 1-year-old male. Pediatr Emerg Care 1999;15:266-7.
17. Bond GR, Thompson JD. Olanzapine pediatric overdose. Ann Emerg Med 1999;34:292-3.
18. Anderson DT, Kuwahara T. Thirty-five case studies involving postmortem tissue distribution of olanzapine (Zyprexa) [abstract A95]. In: Spiehler V, editor. Proceedings of the 1998 Joint SOFT/TIAFT International Meeting; 1998 Oct 5-9; Albuquerque (NM). Newport Beach (CA): International Association of Forensic Toxicologists and Centre of Behavioural and Forensic Toxicology. p. 113.
19. Zyprexa product monograph. Toronto: Eli Lilly Canada Inc.; 1996 Oct 23.
20. Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens - when does therapeutic become toxic? J Forensic Sci 2000;45:418-21.
21. Elian AA. Fatal overdose of olanzapine. Forensic Sci Int 1998;91:231-5.
22. Stephens BG, Coleman DE, Baselt RC. Olanzapine-related fatality. J Forensic Sci 1998;43:1252-3.
23. Gerber JE, Cawthon B. Overdose and death with olanzapine. Am J Forensic Med Pathol 2000;21:249-51.
24. Levine BS, Wu SC, Smialek JE. Olanzapine concentrations in forensic investigations [abstract A114]. In: Spiehler V, editor. Proceedings of the 1998 Joint SOFT/TIAFT International Meeting; 1998 Oct 5-9; Albuquerque (NM). Newport Beach (CA): International Association of Forensic Toxicologists and Centre of Behavioural and Forensic Toxicology. p. 114.
25. Litovitz TL, Klein-Schwartz W, Caravati EM, Youniss J, Crouch B, Lee S. 1998 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1999;17:435-87.
26. Wong SHY, Gock SB, Venuti SE, Stormo A, Greenbaum VJ, Biedrzycki LM, et al. Olanzapine associated deaths: a report of five cases [abstract A97]. In: Spiehler V, editor. Proceedings of the 1998 Joint SOFT/TIAFT International Meeting; 1998 Oct 5-9; Albuquerque (NM). Newport Beach (CA): International Association of Forensic Toxicologists and Centre of Behavioural and Forensic Toxicology. p. 115.
27. Cadario B. Olanzapine (Zyprexa): suspected serious reactions. Can Adverse Drug React Newsl 2000;10:2-3.
28. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol 2001;399:1-14.
29. Nasrallah HA, White TR, Nasrallah AT. Lower mortality in geriatric patients receiving atypical antipsychotics compared to haloperidol [abstract A183]. Biol Psychiatry 2001;49:525.
30. Capel MM, Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol 2000;3:51-4.
31. Gardner DM, Milliken J, Dursun SM. Olanzapine overdose. Am J Psychiatry 1999;156:1118-9.
32. Pounder DJ, Jones GR. Post-mortem drug distribution: a toxicological nightmare. Forensic Sci Int 1990;45:253-63.
33. Jones GR, Pounder DJ. Site dependence of drug concentrations in postmortem blood - a case study. J Ann Toxicol 1987;1195:186-90.
34. Stevens HM. The stability of some drugs and poisons in putrefying human liver tissues. J Forensic Soc 1984;24:577-89.
35. Perry BJ, Sanger T, Beasley C. Olanzapine serum concentrations and clinical response in acutely ill patients. J Clin Psychopharmacol 1997;17:472-7.
36. Hiemke C, Gerek S, Weigmann H, Hartter S. Monitoring serum levels of olanzapine [abstract P.01.247]. Int J Neuropsychopharmacol 2000;3:S158.
37. Ereshefsky L. Pharmacokinetics and drug interactions update for new antipsychotics. J Clin Psychiatry 1996;57:12-5.
38. Xue L, Crookham SB, Diamond FX, Davis PJ, Reiber TM. Development of a gas chromatographic method for the determination of olanzapine in human serum, and a report of patient values abstract 450]. Clin Chem 1998;44:A103.
39. Prior T, Chue P, Tibbo P, Baker G. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999;9:301-9.
40. Brown RP, Kocsis JH. Sudden death and antipsychotic drugs. Hosp Community Psychiatry 1984;35:486-91.
41. Appleby L, Thomas S, Ferrier N, Lewis G, Shaw J, Amos T. Sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2000;176:405-6.
42. Chute D, Grove C, Rajasekhara B, Smialek JE. Schizophrenia and sudden death: a medical examiner case study. Am J Med Pathol 1999;20:131-5.
43. Ruschena D, Mullen PE, Burgess P, Cordner SM, Barry-Walsh J, Drummer OH, et al. Sudden death in psychiatric patients. Br J Psychiatry 1998;172:331-6.
44. Coulter DM, Bate A, Meyboom RHB, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001;322:1207-9.
45. Schreinzer D, Frey R, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S. Different fatal toxicity of neuroleptics identified by autopsy. Eur Neuropsychopharmacol 2001;11:117-24.
46. Welch R, Chue P. Atypical antipsychotics and QT change. J Psychiatry Neurosci 2000;25:154-60.
47. Curkendall SM, Jingping M, Jones JK, Glasser D. Increased cardiovascular disease in patients with schizophrenia. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans. Washington: American Psychiatric Association; 2001.
48. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11:25-32.
49. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and triglyceride levels. J Clin Psychiatry 1999;60:767-70.
50. Melkersson KI, Hulting AL, Brismer KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-9.